Skip to main content

Table 2 Analysis criteria that mention why use the short panel

From: KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response

Criteria Short painel
Steps required The number of steps for executing the Sanger sequencing method of each analyzed exon is the same. However, the number of exons studied in the short panel is smaller.
Time The time spent from the extraction of DNA to the analysis of the results is the same per exon studied, however it becomes smaller when we consider that the short panel presents a reduction in the number of exons studied.
Cost The steps of the Sanger sequencing encompass DNA extraction, PCR, amplicon purification, forward and reverse sequencing PCR, capillary sequencing and analysis. In each of these steps specific kits and reagents are used. The reduction of target exons allows more tests to be performed with the same amount of reagents, which contributes to the reduction of expenses in the diagnostic routine.
Sensibility It is the same, because the proposal is the use of the same methodology.
Specificity The specificity of the method is the same. However, we understand that when evaluating only two exons we will have lower specificity of mutation detection and therefore the short panel is a proposal of screening.
Interpretation The interpretation becomes more concise, objective and fast for technical managers, reducing misinterpretations.
Final consideration Considering all of the foregoing analyzed globally, the application of short panel has impact on the cost and time of release of results to the physician, allowing a rapid approach to patients eligible for treatment with the target therapy.